Straits Times Index
3,204.82 +2.01 (+0.06%) Nikkei
32,402.41 -168.62 (-0.52%) Hang Seng
18,057.45 +402.04 (+2.28%) FTSE 100
7,683.91 +5.29 (+0.07%) Bitcoin USD
26,607.72 +21.29 (+0.08%) CMC Crypto 200
567.63 -0.42 (-0.07%)
GILD Jan 2025 60.000 call
| Previous close | 19.65 |
| Open | 19.65 |
| Bid | 19.00 |
| Ask | 19.25 |
| Strike | 60.00 |
| Expiry date | 2025-01-17 |
| Day's range | 19.65 - 19.65 |
| Contract range | N/A |
| Volume | |
| Open interest | 106 |
Motley Fool3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
ZacksGilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Business WireCHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
FOSTER CITY, Calif., September 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can
